Bahrick, A (2008). Persistence of sexual dysfunction side effects after discontinuation of antidepressant medications: emerging evidence. The Open Psychology Journal
Breggin, P (2008). Brain-Disabling Treatments in Psychiatry. Springer Publishing Company: New York.
Dorph-Petersen, KA, Pierri, JN, Perel, JM, Sun, Z, Sampson, AR, Lewis, DA (2005). The influence of chronic exposure to antipsychotic medications on brain size before and after tissue fixation: a comparison of haloperidol and olanzapine in macaque monkeys. Neuropsychopharmacology
Dubovsky, SL, Davies, R, Dubovsky, AN (2002). Mood disorders. In Textbook of Clinical Psychiatry, 4th ed. (ed. Hales, RE and Yudofsky, SC), pp. 439–542. American Psychiatric Publishing: Washington, DC.
Fava, GA, Gatti, A, Belaise, C, Guidi, J, Offidani, E (2015). Withdrawal symptoms after selective serotonin reuptake inhibitor discontinuation: a systematic review. Psychotherapy & Psychosomatics
Healy, D, Farquhar, G (1998). Immediate effects of droperidol. Human Psychopharmacology
Ho, BC, Andreasen, NC, Nopoulos, P, Arndt, S, Magnotta, V, Flaum, M (2003). Progressive structural brain abnormalities and their relationship to clinical outcome: a longitudinal magnetic resonance imaging study early in schizophrenia. Archives of General Psychiatry
Hughes, S, Cohen, D (2011). Can online consumers contribute to drug knowledge? A mixed-methods comparison of consumer-generated and professionally controlled psychotropic medication information on the internet. Journal of Medical Internet Research
Huxley, A (1954). Doors of Perception. Chatto & Windus: London.
Hyman, SE, Nestler, EJ (1996). Initiation and adaptation: a paradigm for understanding psychotropic drug action. American Journal of Psychiatry
Kendler, KS, Schaffner, KF (2011). The dopamine hypothesis of schizophrenia: an historical and philosophical analysis. Philosophy, Psychiatry & Psychology
Li, M (2016). Antipsychotic-induced sensitization and tolerance: behavioral characteristics, developmental impacts, and neurobiological mechanisms. Journal of Psychopharmacology
Moncrieff, J (2006). Why is it so difficult to stop psychiatric drug treatment? It may be nothing to do with the original problem. Medical Hypotheses
Moncrieff, J (2008). The Myth of the Chemical Cure: A Critique of Psychiatric Drug Treatment. Palgrave Macmillan: Basingstoke, Hampshire, UK.
Moncrieff, J (2009). A critique of the dopamine hypothesis of schizophrenia and psychosis. Harvard Review of Psychiatry
Moncrieff, J (2013). The Bitterest Pills: The Troubling Story of Antipsychotic Drugs. Palgrave Macmillan: London.
Moncrieff, J, Cohen, D (2005). Rethinking models of psychotropic drug action. Psychotherapy & Psychosomatics
Moncrieff, J, Cohen, D (2006). Do antidepressants cure or create abnormal brain states?
Moncrieff, J, Cohen, D, Mason, JP (2009). The subjective experience of taking antipsychotic medication: a content analysis of Internet data. Acta Psychiatrica Scandinavica
Murphy, FC, Smith, KA, Cowen, PJ, Robbins, TW, Sahakian, BJ (2002). The effects of tryptophan depletion on cognitive and affective processing in healthy volunteers. Psychopharmacology (Berlin)
Pellegrino, ED (1976). Prescribing and drug ingestion symbols and substances. Drug Intelligence & Clinical Pharmacy
Samaha, AN, Seeman, P, Stewart, J, Rajabi, H, Kapur, S (2007). ‘Breakthrough’ dopamine supersensitivity during ongoing antipsychotic treatment leads to treatment failure over time. Journal of Neuroscience
Schmeid, K, Ernst, K (1983). Isolierung and zwangsinjektion in urteil der betroffenen patienten und des pflegepersonals. Archiv fur Psychiatrie und Nervenkrankenheiten
Stahl, SM (2013). Stahl's Essential Psychopharmacology, 4th edn. Cambridge University Press: Cambridge.
Vernon, AC, Natesan, S, Modo, M, Kapur, S (2011). Effect of chronic antipsychotic treatment on brain structure: a serial magnetic resonance imaging study with ex vivo and postmortem confirmation. Biological Psychiatry
Vinkers, CH, Olivier, B (2012). Mechanisms underlying tolerance after long-term benzodiazepine use: a future for subtype-selective GABA(A) receptor modulators?
Advances in Pharmacological Science